Amgen's trebananib hits main goal in ovarian cancer trial

06/13/2013 | American City Business Journals

Amgen's experimental drug trebananib, or AMG 386, in combination with paclitaxel, achieved the primary goal of a late-stage study by extending progression-free survival in patients with ovarian cancer. Patients who took trebananib survived 7.2 months without their disease worsening compared with 5.4 months for those in the control group.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA